Clinical Review | Normal Pressure Hydrocephalus | 10.5281.cjn.16332473

Normal Pressure Hydrocephalus (NPH) is a treatable neurological syndrome predominantly affecting the elderly, characterized by a classic triad of gait disturbance, cognitive impairment, and urinary incontinence. Despite its name, NPH involves abnormal cerebrospinal fluid (CSF) dynamics, including intermittent pressure elevations and increased outflow resistance, leading to ventricular enlargement. While often misdiagnosed due to symptomatic overlap with more common neurodegenerative conditions like Alzheimer's and Parkinson's disease, NPH is one of the few reversible causes of dementia, making accurate and timely diagnosis clinically critical. The diagnostic process is multimodal, integrating clinical evaluation, specific neuroimaging markers, and invasive prognostic tests (CSF drainage). The primary therapeutic intervention is surgical CSF shunting, which provides substantial symptomatic relief in a majority of well-selected patients, but necessitates a chronic, lifelong management approach due to potential long-term complications. Future research aims to develop non-invasive biomarkers and novel therapeutic technologies to improve diagnosis and treatment.

II. Introduction to NPH: Historical Context and Evolving Understanding

NPH was first described in 1965 by Salomón Hakim and Raymond Adams, who observed a distinct clinical syndrome with a "classic triad" of gait disturbance, dementia, and urinary incontinence, occurring despite "normal" CSF pressure upon lumbar puncture. Crucially, they demonstrated that symptoms were "dramatically reversed by diverting CSF through a surgical shunt, establishing NPH as one of the very few treatable causes of dementia."

The term "normal pressure" is a "potential misnomer" as continuous intracranial pressure (ICP) monitoring often reveals "intermittent elevations of ICP, particularly B-waves," and a "pathologically elevated resistance to CSF outflow (Rout)." NPH is now understood as a chronic, compensated hydrocephalus where ventricular expansion occurs due to abnormal CSF dynamics, normalizing mean pressure at the expense of brain tissue.

Modern guidelines emphasize gait disturbance as the "most common, most prominent, and typically the earliest symptom," present in "nearly all patients." A characteristic gait impairment is now a mandatory criterion for "probable idiopathic NPH" accompanied by at least one other classic symptom, encouraging earlier diagnosis. NPH is classified as a communicating hydrocephalus, meaning there's "no macroscopic obstruction" within the ventricular system; the core pathology lies in "impaired ability of the arachnoid granulations and other clearance pathways to reabsorb CSF."

NPH is categorized into:

• Idiopathic Normal Pressure Hydrocephalus (iNPH): The most prevalent form, defined by the absence of an identifiable cause, almost exclusively affects individuals "after the age of 60 or 65" with insidious onset over "at least three to six months."
• Secondary Normal Pressure Hydrocephalus (sNPH): Occurs due to a "known neurological event or condition," such as "subarachnoid hemorrhage," "severe traumatic brain injury (TBI)," or "meningitis." sNPH can affect any age and often has a "better prognosis and a more robust and predictable response to CSF shunting."

NPH is a significant public health issue, with prevalence rising dramatically with age (e.g., "0.2% in individuals aged 70–79" to "5.9% in those aged 80 and older"). It is estimated to account for "as many as 6% of all dementia cases in the elderly population," yet is "significantly underdiagnosed" with "over 80% of them undiagnosed or misdiagnosed" due to symptomatic overlap with Alzheimer's and Parkinson's.

III. Pathophysiology of NPH: A Complex Interplay

The pathophysiology of NPH is not fully understood but involves impaired CSF absorption, abnormal pulsatile dynamics, and compromised cerebral health.

• Impaired CSF Absorption: The central defect is a "profound impairment in its absorption," not overproduction. The brain produces "400 to 600 mL per day" of CSF, which is normally reabsorbed through arachnoid granulations. In NPH, this balance is disrupted, leading to gradual fluid accumulation and an "elevated resistance to CSF outflow (Rout)," measurable by a CSF infusion test. This elevated Rout is a "strong predictor of a favorable response to shunt surgery."
• The "Water-Hammer" Pulse and Periventricular Damage: Despite "normal" mean ICP, the "pulsatile dynamics of the CSF are profoundly abnormal." Reduced compliance in NPH leads to a "water-hammer" pulse, where CSF pulse pressure can be "elevated by as much as six to eight times the normal level." This chronic mechanical stress causes "stretching, compression, and interstitial edema" in the periventricular white matter, explaining why "gait disturbance and urinary incontinence are such early and prominent features."
• Impaired Cerebral Blood Flow and the Glymphatic System: Ventricular expansion and edema lead to "compression of the small blood vessels" and a "measurable reduction in cerebral blood flow (CBF)," particularly in the frontal lobes, contributing to cognitive symptoms. The recently discovered glymphatic system, crucial for clearing metabolic waste, is also thought to be disrupted in NPH, potentially leading to "accumulation of toxic metabolites" and explaining overlap with other neurodegenerative disorders.
• Emerging Theories: The "Two-Hit" Hypothesis and Vascular Comorbidities: The "two-hit" hypothesis proposes that iNPH results from:
• Hit 1: Benign External Hydrocephalus (BEH) in Infancy: A mild, often asymptomatic communicating hydrocephalus leading to congenitally larger intracranial volumes and slightly enlarged ventricles.
• Hit 2: Deep White Matter Ischemia (DWMI) in Late Adulthood: Age-related cerebrovascular disease causes damage to white matter, increasing "resistance to the flow of CSF through the brain's extracellular space," triggering symptomatic ventricular enlargement. This theory unifies mechanical, structural, and vascular elements, explaining the strong link between iNPH and "vascular comorbidities," present in "over 60% of patients." The clinical and radiological overlap with subcortical small vessel disease (SSVD) is significant, suggesting a continuum of pathology where "vascular damage impairs CSF clearance, and impaired CSF dynamics, in turn, worsen periventricular perfusion."

IV. Clinical Manifestations and Differential Diagnosis

NPH presents with the insidious onset and progressive worsening of its three cardinal symptoms:

• Gait Disturbance: The "most prevalent and typically the earliest symptom," affecting "80% to 95% of patients." It's a "higher-level motor control disorder" or "gait apraxia," characterized by:
• "Magnetic" or "Stuck-to-the-Floor" quality (difficulty initiating steps)
• Shuffling and short steps
• Broad-based stance
• Disequilibrium and "en bloc" turning difficulty
• Freezing episodes
• Cognitive Impairment: Primarily a "frontal-subcortical type," distinct from Alzheimer's. Key features include:
• Psychomotor slowing
• Executive dysfunction (planning, organizing, problem-solving)
• Apathy and reduced interest
• Attention and concentration deficits
• Milder memory impairment (recent recall), typically preserving language, object recognition, and skilled motor tasks.
• Urinary Incontinence: Usually appears "later in the disease course," caused by "loss of supraspinal (i.e., frontal lobe) inhibitory control over the bladder muscle." Manifests as "urinary frequency and urgency" (especially nocturia), leading to "urge incontinence."

Distinguishing NPH from Other Neurodegenerative Disorders (Table 1 Summary):

• Alzheimer's Disease (AD): NPH gait problems "typically precede or occur simultaneously with cognitive decline," while in AD, gait disturbance is late. NPH dementia is executive/psychomotor slowing; AD is profound episodic memory loss with cortical deficits. NPH dementia is "potentially reversible."
• Parkinson's Disease (PD): Both have slow, shuffling gait. PD gait is typically "narrow-based" with stooped posture and reduced arm swing; NPH is broad-based. Cardinal PD signs (resting tremor, rigidity, bradykinesia) are absent in "pure" NPH. PD responds to levodopa; NPH does not.
• Subcortical Small Vessel Disease (SSVD): Most challenging differential, as SSVD can mimic NPH with similar clinical and imaging features. The key differentiator is "response to treatment" (CSF removal), with NPH showing improvement after diagnostic tap/drainage.

V. The Diagnostic Pathway: A Multimodal Approach

Diagnosis is multimodal, aiming to identify shunt candidates.

• Clinical and Neuropsychological Assessment:Detailed history focusing on symptom onset and progression, particularly gait.
• Standardized gait and balance assessment: "Timed Up and Go (TUG) Test," "10-Meter Walk Test," and qualitative observation to objectively document and measure improvement.
• Formal neuropsychological testing to characterize cognitive deficits, especially "frontal-subcortical domains," aiding differential diagnosis and providing a quantitative baseline.
• Structural Neuroimaging (MRI and CT): Mandatory to document ventricular enlargement and exclude other causes. Specific markers suggesting pressure-related hydrocephalus:
• Ventriculomegaly (Evans' Index ≥0.3): Ratio of frontal horn width to skull diameter.
• Disproportionately Enlarged Subarachnoid Space Hydrocephalus (DESH): "Characteristic pattern of enlarged ventricles and Sylvian fissures in combination with narrowed or 'tight' sulci over the high convexity and midline regions." Considered the "most specific radiological sign."
• Narrowed Callosal Angle: "Between 40 and 90 degrees" on coronal MRI, contrasting with wider angles in atrophy.
• Other supportive features: enlarged temporal horns, periventricular hyperintensities, prominent aqueductal "flow void."
• Invasive Diagnostic and Prognostic Testing: Cornerstones for predicting shunt response.
• The CSF Tap Test (Lumbar Puncture): Most common initial test. "Draining a large volume of CSF, typically 30 to 50 mL." A "positive test is defined as a clear, objective improvement in performance." "High positive predictive value (>90%)," but "low negative predictive value (<50%)."
• Extended Lumbar Drainage (ELD): More sensitive and invasive. "Continuous CSF drainage" for "48 to 72 hours." "Widely regarded as the most accurate prognostic test for NPH," with "summary sensitivity of up to 94% and a positive predictive value of 90%." Higher risk of complications (3-4% infection).
• CSF Outflow Resistance (Rout): Measured during a CSF infusion test. "Elevated (>10−12 mmHg/min/mL)" is a "strong, independent predictor of a favorable shunt response."

VI. Therapeutic Interventions for NPH

Management is primarily surgical, aiming to divert excess CSF.

• CSF Diversion via Shunting: The "standard and most effective treatment." "70-90% of patients who undergo shunting experience a meaningful improvement."
• Types of Shunts:Ventriculoperitoneal (VP) Shunt: Most common, draining CSF from ventricles to the peritoneal cavity.
• Ventriculoatrial (VA) Shunt: Less common, draining to the right atrium, for when peritoneum is not viable.
• Lumboperitoneal (LP) Shunt: Drains from lumbar subarachnoid space to peritoneum, less common for NPH.
• Shunt Hardware: Fixed-Pressure vs. Programmable Valves: Programmable valves allow non-invasive adjustment of opening pressure, offering "significant advantage in NPH management" for fine-tuning symptom relief and minimizing overdrainage.
• Endoscopic Third Ventriculostomy (ETV): A shunt-sparing alternative, minimally invasive. A "small opening (a stoma) is then created in the floor of the third ventricle," creating an internal bypass. While standard for obstructive hydrocephalus, its role in communicating NPH is "more controversial." Efficacy varies, with some studies showing comparable improvement to shunts but lower complications, while others report higher failure rates for iNPH. Large trials are ongoing.
• Management of Surgical Complications: Shunting has significant complication rates.
• Shunt Obstruction/Malfunction: "Most common complication," leading cause for revision surgery. Symptoms recur.
• Shunt Infection: Serious, typically within months, requiring shunt removal and antibiotics.
• Overdrainage and Subdural Hematoma: Occurs when CSF drains too quickly, causing low-pressure headaches or brain collapse, tearing bridging veins and causing hematomas. Managed by adjusting programmable valves or surgical evacuation.

VII. Prognosis and Long-Term Outcomes Following Treatment

Prognosis depends on accurate diagnosis, patient selection, and diligent long-term management.

• Predictors of Favorable Shunt Response:Clinical: "Full triad of symptoms," "gait as the initial symptom," and "shorter duration of symptoms (generally less than two years)."
• Diagnostic Test: "Clear, objective improvement" after CSF tap test or ELD, and "elevated CSF Outflow Resistance (Rout)."
• Etiology and Comorbidities: sNPH patients generally have a better response. Significant comorbid neurodegenerative pathology can limit improvement, but "increasing age alone is not considered a contraindication."
• Long-Term Efficacy: Improvement can be "remarkably durable."
• Symptom-Specific Improvement: "Gait... is the symptom most likely to improve and to remain improved over the long term" (83-87% at 5-7 years). Cognition and urinary incontinence also improve initially (80-84%) but are "less likely than gait to remain stable over many years."
• Symptom Recurrence and Shunt Revision: NPH is a "chronic condition requiring lifelong management." "53% in one major long-term study" will require at least one shunt revision, primarily due to "shunt obstruction or malfunction (87% of revisions)." Most revisions (74%) restore clinical improvement.
• Role of Postoperative Rehabilitation and Management: "Comprehensive, multidisciplinary rehabilitation program is crucial." Includes physical, occupational, cognitive, and speech therapy. "Regular follow-up with the neurosurgery team is critical for the life of the patient" to monitor for shunt problems and fine-tune programmable valve settings.

VIII. Future Directions and Emerging Research

Research focuses on improving diagnosis and treatment.

• The Quest for Non-Invasive Biomarkers: A "holy grail" is a reliable blood or CSF biomarker to diagnose, differentiate, and predict outcomes without invasive testing.
• CSF Proteomics: Research shows iNPH is associated with "upregulation of proteins involved in the immune response and coagulation cascade" and "downregulation of proteins related to neuronal signaling."
• Specific Candidate Biomarkers: Panels combining "total-tau (T-tau), amyloid-β 40 (Aβ40), and the inflammatory chemokine MCP-1" have shown promise. "Neurofilament Light Chain (NFL)" is a marker of axonal damage, elevated in iNPH, and linked to severity.
• "Glymphatic Sink" Hypothesis: Explains "misleading" low Aβ42 in iNPH CSF, suggesting impaired clearance rather than deposition. A higher pre-operative "ratio of Aβ42 to Aβ40 (Aβ42/Aβ40)" may predict better cognitive improvement.
• Technological Advances in Gait and Balance Assessment: Instrumented gait analysis using "pressure-sensitive walkways, 3D optoelectronic motion-capture systems, and wearable inertial sensors" provides "highly detailed, quantitative data" for objective measurement and predicting response.
• Novel Therapeutic Strategies:The eShunt System: A "novel endovascularly-implanted shunt" currently in trials, deployed via a femoral vein catheter. Aims to "significantly reduce the risks of infection, obstruction, and overdrainage" by avoiding craniotomy and long subcutaneous catheters.

IX. Conclusion

NPH is a profound clinical paradox: a treatable cause of debilitating symptoms that remains frequently misdiagnosed. Its pathophysiology is complex and multifactorial. Diagnosis requires a "sophisticated, multimodal prognostic evaluation" to determine if a patient is "likely to benefit from CSF diversion." While CSF shunting is effective, its high rate of long-term complications necessitates viewing NPH as a "chronic disease that requires a lifelong commitment to surveillance and management." Key implications for practice include heightened awareness for early gait changes, systematic diagnostic workups, and chronic disease management post-operatively. Future research priorities are developing "reliable, non-invasive biomarkers" and "safer, more durable, and less invasive therapeutic options" to revolutionize patient care.